Novo Nordisk inventory fell 15% Monday after it mentioned its next-generation weight reduction drug did not meet its key objective of displaying that it wasn’t inferior to Eli Lilly’s rival drug.
The drug, CagriSema, did not obtain its major endpoint of demonstrating non-inferiority on weight reduction when in comparison with Eli Lilly’s rival drug tirzepatide after 84 weeks, Novo mentioned in a press release Monday morning.
Tirzepatide is the lively ingredient in Lilly’s mega-blockbuster medicines Mounjaro and Zepbound, which have overtaken Novo Nordisk’s semaglutide, bought as Ozempic and Wegovy, in U.S. prescriptions.
Novo’s Copenhagen-listed shares had been final seen down 15% at 256 Danish kroner, hitting their lowest degree since June 2021.
Eli Lilly‘s inventory rose 3.5% in premarket buying and selling.
Novo Nordisk ADR’s are severely underperforming Eli Lilly shares.
Sufferers taking a 2.4 mg dose of CagriSema achieved a weight lack of 23% after 84 weeks in comparison with 25.5% with a 15 mg dose of tirzepatide, Novo mentioned.
Novo is exploring further trials to check CagriSema, together with higher-dose combos, it mentioned. The corporate has excessive hopes for the drug, which mixes semaglutide and cagrilintide, one other hormone launched within the pancreas that impacts urge for food.
“CagriSema has the potential to be the primary GLP-1/amylin-combination product to succeed in the marketplace for individuals residing with weight problems, documenting that cagrilintide provides to the prevailing advantages of semaglutide and gives clinically significant additive weight reduction results superior to what has been noticed with GLP-1 biology alone,” mentioned Chief Scientific Officer Martin Holst Lange, including that additional trials would “assess the total weight-loss potential of CagriSema.”
Even so, Monday’s trial result’s one other blow to the Danish drugmaker because it fell quick in opposition to a drug already available on the market, and comes after the inventory fell almost 50% in 2025.
Earlier this month, Novo predicted that its gross sales and revenue progress would decline by between 5% and 13% in 2026, as the corporate navigates competitors, decrease costs within the U.S., and the lack of exclusivity for Wegovy and Ozempic in sure markets.
“Folks ought to count on that it goes down earlier than it comes again up,” CEO Mike Doustdar informed CNBC on the time.
